IDEA Collider: Innovation & Asymmetric Learning in Pharma

PureTech Health is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the “BIG” axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and cr...

25 Visions for the Future of Our Species  We now have the tools to transform ourselves and our species. Greater health and longevity, enhanced brains, and engineered fertility are in the works. What’s just over the horizon is even more astonishing. We call this the neobiological frontier. The book is a collection of 25 essays, interviews, and works of fiction and art offering a big-picture perspec...

Chapter-by-chapter discussion, covering: opium/ heroin antibiotics contraceptive pill vaccines and more... Find more by Thomas Hager here: https://www.thomashager.net  

Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA) Before Teva, Dr. Levin was m...

The books Annie recommends: Maria Konnikova The Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win   Philip Tetlock, Dan Gardner Superforecasting: The Art and Science of Prediction   Don A Moore Perfectly Confident: How to Calibrate Your Decisions Wisely

Peter on Twitter: https://twitter.com/peterkolchinsky The book's website: https://peterkolchinsky.com/bio Link to the Katherine Eban discussion: 

Deborah Waterhouse, CEO ViiV Healthcare Deborah was appointed to GSK’s Corporate Executive Team on 8th January 2020. She became Chief Executive Officer of ViiV Healthcare on 1st April 2017. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders. In this interview, we discuss cultures of innovation, innovation in the business model, purpose-driven innovation...

For more on JLABS, go to https://jlabs.jnjinnovation.com/JLABSNavigator#/ As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure...

In an archive recording, from 2015, the author of one of the best pharma-related books of the past decade, Clifton Leaf, gives us an insight into The Truth In Small Doses, Why We're Losing the War on Cancer-and How to Win It. (In this case, archive means that we thought we had lost the file, and then found it in a place we didn't expect!) Clifton, now Editor In Chief at Fortune Magazine, remains o...

Links to the papers we discuss Diagnosing the Decline of Pharmaceutical R&D efficiency (2012): https://www.nature.com/articles/nrd3681 When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis (2016): https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147215 Pharmaceutical Evolution: Clinical Selection versus Intelligent Design: https://www.innoge...

Discussion of the new Matt Ridley book, How Innovation Works, published in May 2020. http://www.mattridley.co.uk Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, The Origins of Virtue, Genome, Nature via Nurture, Francis Crick, The Rational Optimist and The Evolution of Everything. His TED talk "When Ide...

Why Boston/ Cambridge and South San Francisco? Why not New York? Cultures of innovation The new way, scaling start-ups Critical factors for biotech hubs Europe/ The UK and the rest of the world Where does innovation come from? How is it defined?

Interview with Vinayak K. Prasad, author of Malignant: How Bad Policy and Bad Evidence Harm People with Cancer An essential listen for anyone involved in cancer R&D. Vinay is one of the more interesting voices on Twitter (@VPrasadMDMPH), and the book presents a wonderful exploration of what's right with oncology R&D and what's wrong. The interview reveals how positively he sees the opportunity to...

IDEA Pharma: IDEA Collider Jackie Hunter    https://www.youtube.com/watch?v=K59qefVIsbA     Interviewer: So welcome to another series of IDEA Collider with leaders in innovation. I'm delighted to be joined by Jackie Hunter of Benevolent AI. First of all, would you like to tell us more about you and about Benevolent?   Jackie Hunter: Yeah, I'm a board director of Benevolent AI. I've been with the c...

0:00 Defining innovation 01:00 Incremental innovation vs big changes 01:45 On designing back from the unmet need, and introducing innovation (Interruption by a phone call �) 02:54 Problem backwards vs solution forwards 03:55 On the ‘guided random walk’ and adoption of agility/ serendipity (low validity environments in pharma) 04:45 Prediction, hubris and certainty in process 06:50 The stopping rul...

IDEA Pharma: IDEA Collider Mike Rea talks with Joseph Owens from Google X   https://vimeo.com/269261531     Joseph Owens: Good to see you.    Mike Rea: Thanks for coming over. So, this is just for the benefit of everyone who has seen the previous live streams with me talking [in the camera]. This is hopefully the start of a new series of live streams and recordings where we're going to interview p...

00:20 Introduction: what does Silicon Valley Bank's Life Sciences and Healthcare group do? 01:00 Nooman's background 01:30 How does SVB fit into the innovation ecosystem? 02:00 Lending to companies who don't have products 02:15 How does innovation happen: the myth of the lone inventor; the value of connections 03:15 Parallels to non-pharma innovation models and ecosystems 03:45: Innovation as the...

Mike Rea in conversation with Katherine Eban. Katherine's website The book, on Amazon  

https://www.youtube.com/watch?v=AgUJQtQUrEs   IDEA Pharma: A Conversation with Dr. Menelas Pangalos of AstraZeneca   Mike Rea:                          Just a quick note this is Menelas Pangalos, can I have your official title?   Dr. Menelas Pangalos:       I am EVP of Innovative Medicines and early development. I’m at Biotech Unit and also Global Business Development.   Mike Rea:                 ...

John Carroll can be found at: @johncendpts on Twitter or www.endpts.com

Opens with intro of Safi Bahcall Discussion of leadership of innovation S and P innovation Pharmaceutical examples Culture vs incentives Serendipity and prediction